Triazine-based tyrosinase inhibitors identified by chemical genetic screening.
As most of the available depigmenting agents exhibit only modest activity and some exhibit toxicities that lead to adverse side effects after long-term usage, there remains a need for novel depigmenting agents. Chemical genetic screening was performed on cultured melanocytes to identify novel depigmenting compounds. By screening a tagged-triazine library, we identified four compounds, TGH11, TGD10, TGD39 and TGJ29, as potent pigmentation inhibitors with IC50 values in the range of 10 microM. These newly identified depigmenting compounds were found to function as reversible inhibitors of tyrosinase, the key enzyme involved in melanin synthesis. Tyrosinase was further confirmed as the cellular target of these compounds by affinity chromatography. Kinetic data suggest that all four compounds act as competitive inhibitors of tyrosinase, most likely competing with L-3,4-dihydroxyphenylalanine (L-DOPA) for binding to the DOPA-binding site of the enzyme. No effect on levels of tyrosinase protein, processing or trafficking was observed upon treatment of melanocytes with these compounds. Cytotoxicity was not observed with these compounds at concentrations up to 20 muM. Our data suggest that TGH11, TGD10, TGD39 and TGJ29 are novel potent tyrosinase inhibitors with potential beneficial effects in the treatment of cutaneous hyperpigmentation.
Ni-Komatsu
Li
L
The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA.
Leung
Jennifer K
JK
Williams
Darren
D
Min
Jaeki
J
Khersonsky
Sonya M
SM
Chang
Young-Tae
YT
Orlow
Seth J
SJ
D000818:Animals; D000951:Antigens, Neoplasm; D001665:Binding Sites; D001667:Binding, Competitive; D002478:Cells, Cultured; D002846:Chromatography, Affinity; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005820:Genetic Testing; D007700:Kinetics; D007980:Levodopa / Q000378:metabolism; D058965:MART-1 Antigen; D008543:Melanins / Q000378:metabolism; D008544:Melanocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D014442:Monophenol Monooxygenase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009363:Neoplasm Proteins / Q000378:metabolism; D010858:Pigmentation / Q000187:drug effects; D021381:Protein Transport; D014227:Triazines / Q000494:pharmacology*
D000951:Antigens, Neoplasm; D004791:Enzyme Inhibitors; D058965:MART-1 Antigen; D008543:Melanins; C548668:Mlana protein, mouse; D009363:Neoplasm Proteins; D014227:Triazines; D007980:Levodopa; D014442:Monophenol Monooxygenase